XCancer

LU-TARGET: A Phase 1 Study of Lutetium-177-PSMA-617 Adjuvant Radiotherapy for IDH Wild Type Gliomas Expressing PSMA Following Standard Treatment

Description:

The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.

Sponsor:

Memorial Sloan Kettering Cancer Center

Phase:

Phase 1

Contacts:

Thomas Kaley, MD

kaleyt@mskcc.org

212-639-5122

Brandon Imber, MD

imberb@mskcc.org

631-212-6346

Government Study Link:

NCT07223034 - Click here to see study on

ClinicalTrials.gov

68Ga-PSMA

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

Isotope(s):
Target(s):
  • PSMA